Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab-Reference-Cited by-同舟云学术

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

Published:2018-08-06 Issue:9 Volume:24 Page:1441-1448
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Gandara David R.,Paul Sarah M.,Kowanetz Marcin,Schleifman Erica,Zou Wei,Li Yan,Rittmeyer Achim,Fehrenbacher Louis,Otto Geoff,Malboeuf Christine,Lieber Daniel S.,Lipson Doron,Silterra Jacob,Amler Lukas,Riehl Todd,Cummings Craig A.,Hegde Priti S.,Sandler Alan,Ballinger Marcus,Fabrizio David,Mok Tony,Shames David S.

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-018-0134-3.pdf

Reference38 articles.

1. Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255–265 (2017).

2. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).

3. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).

4. Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).

5. Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837–1846 (2016).

Cited by 938 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials;Science China Life Sciences;2024-09-12

2. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer;Cell & Bioscience;2024-09-12

3. A Complete Response in a Metastatic Melanoma Patient After a Single Dose of Dual Checkpoint Inhibitors Blockade Could Be Predictable: A Case Report;Cureus;2024-09-12

4. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities;Nature Reviews Cancer;2024-09-02

5. Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer;Cancer Cell;2024-09